JP7061568B2 - オピオイド新生児薬物離脱症候群の処置及び予防 - Google Patents

オピオイド新生児薬物離脱症候群の処置及び予防 Download PDF

Info

Publication number
JP7061568B2
JP7061568B2 JP2018535324A JP2018535324A JP7061568B2 JP 7061568 B2 JP7061568 B2 JP 7061568B2 JP 2018535324 A JP2018535324 A JP 2018535324A JP 2018535324 A JP2018535324 A JP 2018535324A JP 7061568 B2 JP7061568 B2 JP 7061568B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
opioid
drug
naltrexol
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018535324A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501194A (ja
JP2019501194A5 (enExample
Inventor
ウォルフガング・サディー
ジョン・オーバーディック
Original Assignee
オハイオ・ステイト・イノベーション・ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オハイオ・ステイト・イノベーション・ファウンデーション filed Critical オハイオ・ステイト・イノベーション・ファウンデーション
Publication of JP2019501194A publication Critical patent/JP2019501194A/ja
Publication of JP2019501194A5 publication Critical patent/JP2019501194A5/ja
Application granted granted Critical
Publication of JP7061568B2 publication Critical patent/JP7061568B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
JP2018535324A 2016-01-08 2017-01-06 オピオイド新生児薬物離脱症候群の処置及び予防 Active JP7061568B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276691P 2016-01-08 2016-01-08
US62/276,691 2016-01-08
PCT/US2017/012452 WO2017120417A1 (en) 2016-01-08 2017-01-06 Treatments and prevention of opioid neonatal abstinence syndrome

Publications (3)

Publication Number Publication Date
JP2019501194A JP2019501194A (ja) 2019-01-17
JP2019501194A5 JP2019501194A5 (enExample) 2020-01-23
JP7061568B2 true JP7061568B2 (ja) 2022-04-28

Family

ID=59274434

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018535324A Active JP7061568B2 (ja) 2016-01-08 2017-01-06 オピオイド新生児薬物離脱症候群の処置及び予防

Country Status (8)

Country Link
US (3) US10925870B2 (enExample)
EP (1) EP3400066B1 (enExample)
JP (1) JP7061568B2 (enExample)
CN (1) CN108778423A (enExample)
AU (1) AU2017206041B2 (enExample)
CA (1) CA3010609A1 (enExample)
DK (1) DK3400066T3 (enExample)
WO (1) WO2017120417A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL277801B2 (en) * 2018-04-09 2025-06-01 Katana Pharmaceuticals Inc Oxytocin compositions and methods of use
US20220047580A1 (en) * 2019-01-04 2022-02-17 Aether Therapeutics Inc. Method for treating drug or alcohol dependency
US10653690B1 (en) * 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery
EP4366736A4 (en) * 2021-07-06 2025-05-14 Aether Therapeutics Inc. LOW-DOSE NALTREXOL AND USES THEREOF
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069262A1 (en) 2000-03-15 2003-04-10 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
US20060111308A1 (en) 2004-11-16 2006-05-25 Wendye Robbins Methods and compositions for therapeutic treatment
US20060240085A1 (en) 2003-07-25 2006-10-26 Euro-Celtique S.A. Treatment of dependence withdrawal

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500686A (ja) 2007-10-18 2011-01-06 アイコ バイオテクノロジー オピオイドと中性アンタゴニストを用いる組合せ鎮痛剤
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
WO2009079489A1 (en) * 2007-12-17 2009-06-25 The Ohio State University Research Foundation Methods for screening of opioid receptor neutral antagonists and inverse agonists and uses thereof
CN102307895A (zh) * 2008-12-04 2012-01-04 里兰斯坦福初级大学理事会 用于治疗或预防麻醉药停药症状的方法和组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069262A1 (en) 2000-03-15 2003-04-10 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
US20060240085A1 (en) 2003-07-25 2006-10-26 Euro-Celtique S.A. Treatment of dependence withdrawal
US20060111308A1 (en) 2004-11-16 2006-05-25 Wendye Robbins Methods and compositions for therapeutic treatment

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ClinicalTrials.gov，2014年06月26日，NCT01965704
DEBELAK, Kimber et al.，The American Journal of Addictions，2013年，Vol. 22, Issue 3，pp. 252-254，https://doi.org/10.1111/j.1521-0391.2012.12005.x
ELKOMY, MH. et al.，CLINICAL PHARMACOLOGY & THERAPEUTICS，2015年02月，Vol. 97, No. 2，pp. 167-176，https://doi.org/10.1002/cpt.5
WIEGAND, Samantha L. et al.，OBSTETRICS & GYNECOLOGY，2015年02月，Vol. 125, Issue 2，pp. 363-368，https://doi.org/10.1097/AOG.0000000000000640

Also Published As

Publication number Publication date
NZ744112A (en) 2025-05-30
US20210205296A1 (en) 2021-07-08
CA3010609A1 (en) 2017-07-13
US10925870B2 (en) 2021-02-23
JP2019501194A (ja) 2019-01-17
WO2017120417A1 (en) 2017-07-13
CN108778423A (zh) 2018-11-09
US20190015406A1 (en) 2019-01-17
US20250177379A1 (en) 2025-06-05
EP3400066A4 (en) 2019-06-26
AU2017206041A1 (en) 2018-07-26
EP3400066A1 (en) 2018-11-14
US12161641B2 (en) 2024-12-10
AU2017206041B2 (en) 2022-07-28
DK3400066T3 (da) 2021-10-18
EP3400066B1 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
JP7061568B2 (ja) オピオイド新生児薬物離脱症候群の処置及び予防
JP6929479B2 (ja) 激越の治療のための舌下デクスメデトミジンの使用
Jasiecka et al. Pharmacological characteristics of metamizole
EP3154529B1 (en) Orally disintegrating tablet containing solid lipid particles and methods for their preparation and use
PT1478399E (pt) Forma de dosagem oral contendo um inibidor de pde 4 como um ingrediente activo e polivinilpirrolidona como excipiente
TWI483738B (zh) 具有改良之味道遮蔽性的擠出物
US20200255436A1 (en) Corticotropin releasing factor receptor antagonists
KR20160011205A (ko) 히드로코티손을 포함하는 조성물
JP2025506498A (ja) 特発性肺線維症の処置のためのブロキシブチドの使用
TW202247844A (zh) 吡咯并嘧啶類化合物的用途
WO2017084631A1 (zh) 预防或治疗脂肪胰、改善脂肪胰引起的胰病变、糖尿病或其他相关病症之组合物及方法
HK1260764A1 (en) Treatments and prevention of opioid neonatal abstinence syndrome
CN108472274B (zh) 用于预防或减少经皮水分流失的组合物
WO2017059726A1 (zh) 癸酸甘油三酯类化合物在制备治疗多囊卵巢综合症药物中的应用
WO2017113775A1 (zh) 甘油三酯类化合物在制备治疗神经退行性疾病药物中的应用
JP2016518440A (ja) 炎症性腸疾患の処置のためのチアゾロピリミジノンの使用
HK1141996A (en) Improved taste-masking extrudates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220104

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220104

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220118

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220222

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220301

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220418

R150 Certificate of patent or registration of utility model

Ref document number: 7061568

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250